ABSTRACT
Metabolic bone diseases include a group of diseases in which the skeletal system is widely affected and increased bone formation and destruction with increased Tc-99m-marked diphosphonate uptake is observed in bone scintigraphy. Increased radioactive material uptake observed in bone scintigraphy mostly develops secondary to increased osteoblastic activity and less frequently increased vascular structure. Therefore, bone scintigraphy, a functional imaging of the entire skeletal metabolism plays an important role in the diagnosis of metabolic bone diseases, evaluation of complications and response to treatment. In this compilation, the role of bone scintigraphy and other radionuclide imaging methods in the evaluation of metabolic bone diseases is explained.
References
1Cook GJR, Gnanasegaran G, Chua S. Miscellaneous indications in bone scintigraphy: metabolic bone diseases and malignant bone tumors. Semin Nucl Med 2010;40:52-61.
2Elgazzar AH, Silberstein EB. Skeletal scintigraphy in non-neoplastic osseous disorders. In: Henkin. RE, Bova D, Dillehay GL et al (Eds). Nuclear Medicine 2nd Edition. Phiadelphia: Mosby, Elsevier; 2006: p. 1121-1181.
3Abdelrazek S, Szumowski P, Rogowski F. et al. Bone scan in metabolic bone diseases. Nucle Med Rev 2012;15:124-131.
4Yoder JS, Kogan F, Gold GE. PET-MRI for the study of metabolic bone disease. Curr Osteoporos Rep 2018;16:665-673.
5Fogelman I, Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease. Clin Radiol 1980;31:321-326.
6Sager S, Aliyev A, Halaç M et al. Positron emission tomography/computed tomography imaging of Brown tumors mimicking multiple skeletal metastases in patient with primary hyperparathyroidism. Indian J Endocrinol Metab 2012;16:850-852.
7Gedik GK, Ata Ö, Karabağlı P, et al. Differential diagnosis between secondary and tertiary hyperparathyroidism in a case of a giant-cell and brown tumor containing mass. Hell J Nucl Med 2014;17:214-217.
8Kuwahara K, Izawa S, Murabe H, et al. Increased 18F-fluorodeoxyglucose uptake in a brown tumor in a patient with primary hyperparathyroidism. J Clin Endocrinol Metab 2007;92:2408-2409.
9Magee M, White CP, Murray IPC. Growth and metabolic disorders. In: Ell PJ, Gambhir SS editors. Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd Edition. Churchill: Livingstone; 2004. p. 739-757.
10Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992;38:62-67.
11Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and F18 fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 1993;77:949-955.
12Lawal I, Ankrah A, Ololade K, et al. Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT. Medicine (Baltimore) 2017;96:e8471.
13Ghesani N, Jung J, Patel S, et al. Superscan caued by renal osteodsytrophy: Observed on 18F FDG PET/CT scan. Indian J Nucl Med 2013;28:251-252.
14Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget’s disease of bone. J Nucl Med 1997;38:1495-1497.
15Cook GJ, Blake GM, Marsden PK, et al. Quantification of skeletal kinetic indices in Paget’s disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res 2002;17:854-859.
16Installe J, Nzeusseu A, Bol A, et al. 18F-fluoride PET for monitoring therapeutic response in Pagetic disease of bone. J Nucl Med 2005;46:1650-1658.
17Frost ML, Cook GJ, Blake GM, et al. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. J Bone Miner Res 2003;18:2215-2222.
18Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med 2009;50:1808-1814.
19Schmitz A, Risse JH, Textor J, et al. FDG- PET findings of vertebral compression fractures in osteoporosis: preliminary results. Osteoporos Int 2002;13:755-761.
20Kato K, Aoki J, Endo K. Utility of FDG PET in differential diagnosis of benign and malignant fractures in acute to subacute phase. Ann Nucl Med 2003;17:41-46.
